This Biotech’s Stock Soaring After FDA Official Exits
Biotech stocks surged after news that a polarizing FDA official is stepping down. The rally centers on this biotech’s...
Which Rebalances More Often Index Fund Or Target Date
Compare rebalancing frequency between index funds and target-date funds and what that means for risk, fees, and long-term performance. A quick look at when to expect adjustments.
28,361 articles
Bitcoin Drops Inflation Hots as Services Spark Rate Shift
Bitcoin slides roughly 3% after hotter-than-expected January PPI data; a surge in services inflation is prompting a f...
Korean Chip Stocks Trading Slump as AI Hype Fades This Week
Korean chip equities are wavering after a blistering AI-driven rally, with the KOSPI retreating and memory peers weig...
PBDC Holders Face Hard Questions About Sustainability
PBDC, a focused BDC ETF, slashed its April 2026 payout by about 14% to $0.71273 per share. With shares near $27 and a...
Here Monday’s Best Wall Street Calls Spark Fresh Market Moves
As earnings season looms, Monday’s best Wall Street calls are guiding early moves in key names. Traders watch multipl...
Mastercard Embracing Crypto: Trying to Lead or Contain It
Mastercard unveiled a large partner program to weave stablecoins and tokenized dollars into its payments network, a m...
Bitcoin (BTC) Recovery Unlikely as Toxic Supply Absorbs
Bitcoin tumbled to fresh weekly lows as on-chain metrics show long-term holders under pressure and exchange inflows r...
Spacex (SPCX) Stock Plunging: Should You Buy the Dip?
When a high-profile stock takes a sharp fall, the instinct to buy the dip can be strong. This guide breaks down how t...
Warren Buffett's Successor, Greg: Alphabet Bets Battle
Two billionaire investors, two very different plays on Alphabet. One backs a measured, Buffett-like approach; the oth...
Bought Rentals, Then Stopped: A $5,000/Deal Pivot Guide
A veteran landlord built a 50-property portfolio, then paused growth to chase higher, more scalable income. This arti...
Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Stock Falling Knife? Is FMC Stock a Buy Now or Not?
FMC stock has seen a sharp drop, prompting questions about value and timing. This guide breaks down how to tell if th...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status